Covid-19. COVID-19, virus not identified
Conditions
Interventions
Intervention 1: Intervention group: 3 capsules containing 2010 mg EPA and DHA + 2 capsules containing 400 mg Hydroxychloroquine. Intervention 2: Control group: 2 capsules containing 400 mg Hydroxychlo
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Body mass index equal to or more than 18.5 age equal to or more than 18 Diabetic patients diagnosed with covid-19 according to physician diagnosis Not consuming any particular diet or supplement as well as not doing any particular physical activity Willingness to participate in the study
Exclusion criteria
Exclusion criteria: Having a history or current diagnosis of inflammatory disorders including liver, kidney or thyroid abnormalities, pancreatitis, any malignancy or other conditions that impact inflammatory status Patients who had regularly received omega-3 supplements during 3 months before our trial Pregnancy Lactating Menopause Patients with history of smoking (at-least 5 cigarette per day) or alcohol intake during 6 months before our trial any abnormality in PTT, PT or INR tests
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte sedimentation rate (ESR). Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Automated erythrocyte sedimentation rate analyzer (ELECTA LAB S.r.l, Via Balzella, Italy).;C-reactive protein. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Immunoturbidimetric method (Pars Azmun, Iran).;Fatigue. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.;Body pain. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.;Appetite. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.;Olfactory. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10. | — |
Secondary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase. Timepoint: In the baseline and after 2 weeks omega-3 supplementation. Method of measurement: Available valid diagnostic test kits (Crest Biosystems kits, India).;Aspartate aminotransferase. Timepoint: In the baseline and after 2 weeks omega-3 supplementation. Method of measurement: Available valid diagnostic test kits (Crest Biosystems kits, India).;Alkaline phosphatase. Timepoint: In the baseline and after 2 weeks omega-3 supplementation. Method of measurement: Available valid diagnostic test kits (Crest Biosystems kits, India). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Abdolahi
Tehran University of Medical Sciences
Outcome results
None listed